Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AuraGen Aesthetics developed the FDA-cleared AuraGen 1–2–3™ with AuraClens™, an automated system for harvesting, filtering, washing, and transferring autologous adipose tissue. The system is clinically proven to provide high fat concentration (>90%), high cell viability (>90%), and superior retention rates (>70%) compared to traditional methods (~40%). It enables efficient processing of both small (<50 ml) and large volumes (<700 ml) of patient fat in under ten minutes. The technology was acquired by Sientra in January 2022 to expand their portfolio beyond breast products into broader aesthetic applications.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on AuraGen Aesthetics.